Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 7/20 | 0.51 |
| ▸ | GRM5 | P41594 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.45 |
| ▸ | KMO | O15229 | 2/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2907018 | 0.85 | MCL1 (0.50) | MCL1P2RY12 | |
| SCHEMBL1201785 | 0.84 | GRM5 (0.50) | MCL1GRM5P2RY12 | |
| SCHEMBL317468 | 0.79 | GRM5 (0.48) | GRM5ADORA1ADORA2AADORA3 | |
| SCHEMBL1111184 | 0.77 | MCL1 (0.64) | MCL1ADORA3 | |
| SCHEMBL986309 | 0.77 | USP30 (0.47) | MCL1P2RY12 | |
| SCHEMBL2578647 | 0.76 | ADORA2A (0.43) | ADORA1ADORA2AADORA3KMOP2RY12 | |
| SCHEMBL2587393 | 0.75 | ADORA2A (0.44) | ADORA1ADORA2AADORA3KMOP2RY12 | |
| SCHEMBL17379469 | 0.74 | GRM5 (0.62) | GRM5 | |
| SCHEMBL4271936 | 0.73 | NPC1 (0.55) | MCL1KMOP2RY12 | |
| SCHEMBL15964704 | 0.73 | OPRK1 (0.47) | GRM5KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081903-B1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-05-07 | — | — | EP | disclosed |
| US-8093250-B2 | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-10 | — | — | US | disclosed |
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-2081903-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008044217-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | P2RY12, P2RY2, P2RY1 | MCL1 3193/4885GRM5 558/4885ADORA1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.